The method, presented at the European Congress of Clinical Microbiology and Infectious Diseases, may provide results in hours rather than a week or more.
The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
Since moving to rapid molecular testing, the lab has doubled its billable test volume, largely through increasing clients for its outreach lab services.
The company is developing a new gold standard comparator test after it encountered problems with typical culture methods it used in developing a new pneumonia assay.
The FDA cleared BD's test for detecting carbapenemase-producing organisms, which can be used by hospitals to contain the spread of antimicrobial resistance.
